Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Seagen Inc
(NQ:
SGEN
)
228.74
UNCHANGED
Last Price
Updated: 4:00 PM EST, Dec 13, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Seagen Inc
< Previous
1
2
3
4
5
Next >
Six-Year Overall Survival Results Added to U.S. Prescribing Information for ADCETRIS® (brentuximab vedotin) as First-Line Treatment for Advanced Hodgkin Lymphoma
June 14, 2023
From
Seagen Inc.
Via
Business Wire
Seagen Announces ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 98% Overall Response Rate and 93% Complete Response Rate in Patients with Early-Stage Classical Hodgkin Lymphoma (cHL)
June 13, 2023
From
Seagen Inc.
Via
Business Wire
3 Stocks Worth Buying at 52-Week Lows
May 30, 2023
Here are three stocks that are trading near their 52-week lows and may be primed for a short-term rally for opportunistic investors
Via
MarketBeat
Seagen Inc. (NASDAQ: SGEN) Climbs to New 52-Week High
March 13, 2023
Via
Investor Brand Network
Seagen Stockholders Approve Acquisition by Pfizer
May 30, 2023
From
Seagen Inc.
Via
Business Wire
Is Pfizer's Seagen Deal In Jeopardy Amid Antitrust Scrutiny?
May 19, 2023
Despite worries about FTC scrutiny, Pfizer remains optimistic about its planned Seagen acquisition, issuing $31 billion in bonds to finance the deal.
Via
MarketBeat
Topics
Bonds
Exposures
Debt Markets
Seagen Reports First Quarter 2023 Financial Results
April 27, 2023
From
Seagen Inc.
Via
Business Wire
SEAGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Seagen Inc. - SGEN
April 26, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
Seagen to Highlight Data From Oncology Portfolio and Pipeline at the 2023 American Society of Clinical Oncology Annual Meeting
April 26, 2023
From
Seagen Inc.
Via
Business Wire
SGEN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Seagen Inc. Is Fair to Shareholders
April 24, 2023
From
Halper Sadeh LLC
Via
Business Wire
Seagen to Report First Quarter 2023 Financial Results on April 27, 2023
April 07, 2023
From
Seagen Inc.
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Univar Solutions Inc. (NYSE - UNVR), Oak Street Health (NYSE – OSH), Seagen Inc. (Nasdaq - SGEN), U.S. Xpress Enterprises, Inc. (NYSE – USX)
April 04, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
FDA Grants Accelerated Approval for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer
April 03, 2023
From
Seagen Inc.
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Oak Street Health (NYSE – OSH), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)
March 23, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
3 Dividend Contenders to Buy Now for Long-Term Gains Later
March 22, 2023
Dividend stocks have a role to play in any portfolio, and this article highlights three dividend contenders that you can buy now to get long-term gains later
Via
MarketBeat
MarketBeat Week in Review – 3/13 - 3/17
March 18, 2023
The first triple witching day of 2023 is a fitting way to end a wild week. As you take some time to relax, here are some of our most popular stories this week
Via
MarketBeat
Topics
ETFs
Economy
Exposures
Interest Rates
Pfizer’s Latest Acquisition Strengthens the Case for PFE Stock
March 15, 2023
Pfizer's merger with Seagen will strengthen the company's already strong oncology portfolio and perhaps boost the case for owning PFE stock
Via
MarketBeat
Seagen to Present New Clinical and Preclinical Data From Broad Portfolio of Targeted Cancer Therapeutics at the 2023 AACR Annual Meeting
March 14, 2023
From
Seagen Inc.
Via
Business Wire
SEAGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Seagen Inc. - SGEN
March 13, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Qualtrics (Nasdaq - XM), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)
March 13, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
SGEN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Seagen Inc. Is Fair to Shareholders
March 13, 2023
From
Halper Sadeh LLC
Via
Business Wire
Pfizer Invests $43 Billion to Battle Cancer
March 13, 2023
From
Seagen Inc.
Via
Business Wire
Astellas and Seagen Announce China’s National Medical Products Administration Accepts Biologics License Application for Enfortumab Vedotin in Certain Patients with Locally Advanced or Metastatic Urothelial Cancer
March 09, 2023
From
Seagen Inc.
Via
Business Wire
Seagen to Present at the Cowen 43rd Annual Health Care Conference
February 27, 2023
From
Seagen Inc.
Via
Business Wire
Seagen Reports Fourth Quarter and Full Year 2022 Financial Results
February 15, 2023
From
Seagen Inc.
Via
Business Wire
Seagen to Highlight Research in Urothelial Cancer at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium
February 13, 2023
From
Seagen Inc.
Via
Business Wire
Seagen Announces FDA Accelerated Approval of TUKYSA® (tucatinib) in Combination with Trastuzumab for People with Previously Treated RAS Wild-Type, HER2-Positive Metastatic Colorectal Cancer
January 19, 2023
From
Seagen Inc.
Via
Business Wire
Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023
January 19, 2023
From
Seagen Inc.
Via
Business Wire
Seagen to Present at the J.P. Morgan Healthcare Conference
December 20, 2022
From
Seagen Inc.
Via
Business Wire
Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
December 20, 2022
From
Seagen Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.